ClinicalTrials.gg
CompletedNCT00817414Updated Jun 2, 2021Results posted

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

A Phase 2 interventional study of LCI699-matching placebo and LCI699 in Hypertension, sponsored by Novartis. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
183rd of 222
63 · median 309
Started
2009
with 16 others
Phase 2
29 of 227
2 open now
Registered
155th of 227
by date

Among the 227 studies in Hypertension by Novartis, this one is the 183rd largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2009, is one of 29 in phase 2, and was the 155th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood Pressure
  • Hypertension
  • Cortisol
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of hypertension with blood pressure ≥ 140/90 millimeters of mercury (mmHg) and \< 180/110 mmHg on current antihypertensive treatment
  • Male and female participants 18-75 years of age
  • Participants must weigh at least 50 kilograms (kg)

Exclusion criteria

Exclusion Criteria:

  • Recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebral accident or
  • electrocardiography () findings related to cardiac conduction defects
  • Type 1 diabetes or uncontrolled type 2 diabetes ( [HbA1c] > 9%)
  • within the last 5 years (excluding basal cell skin cancer)
  • Liver disease

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Cohort A: LCI699 0.5 mg QD

    Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.

    Drug: LCI699

  • Experimental
    Cohort A: LCI699 1.0 mg QD

    Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.

    Drug: LCI699

  • Experimental
    Cohort B1: LCI699 1.0 mg BID

    Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.

    Drug: LCI699

  • Experimental
    Cohort B1: LCI699 2.0 mg QD

    Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.

    Drug: LCI699

  • Placebo comparator
    Placebo

    Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.

    Drug: LCI699-matching placebo

Interventions

  • DrugLCI699-matching placebo

    LCI699-matching placebo oral capsules

  • DrugLCI699

    LCI699 oral capsules

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants

    As per the protocol, MTD is the dose at which 4 participants exhibited ACTH-stimulated cortisol results \<400 nanomoles per liter (nmol/L). The change in the distribution across the treatments were analyzed using 1- way analysis of variance (ANOVA) for continuous variables.

    Time frame: Up to Week 6

Secondary outcomes

  1. LCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants

    Exposure-response relationship was assessed using ACTH stimulation test. Tests were done 2 hours after study drug administration (i.e., at peak LCI699 concentrations). An increase in cortisol greater than \>500 nmol at 60 minutes after ACTH administration was expected.

    Time frame: Up to Week 6

  2. LCI699 Plasma Concentration Post LCI699 Administration at Day 7

    Time frame: Predose and 3 hours post-dose on Day 7

  3. Maximum Plasma Concentration (Cmax) of LCI699

    Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

  4. Time of Maximum Plasma Concentration (Tmax) of LCI699

    Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

  5. Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)

    Time frame: Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

  6. Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699

    Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

  7. Apparent Terminal Half-life (T1/2) of LCI699

    Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

  8. Number of Participants With Adverse Event (AEs)

    An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives.

    Time frame: Up to 8 weeks

  9. Percentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

    Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing blood pressure (BP) and heart rate (HR) measurements were performed. MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.

    Time frame: Week 6

  10. Percentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP

    Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing BP and HR measurements were performed. MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>= 10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.

    Time frame: Week 6

07

Results

Posted Jun 2, 2021

Participant flow

Participants were enrolled at 10 investigative sites in the United States and Iceland from 14 January 2009 to 12 August 2009.

Participant flow — Overall Study
MilestoneCohort A: LCI699 0.5 mg QDCohort A: LCI699 1 mg QDCohort B1: LCI699 1 mg BIDCohort B1: LCI699 2 mg QDPlacebo
Started1212131313
Completed1099111
Not completed234122
Withdrew: Adverse event11100
Withdrew: Low adrenocorticotropic hormone (acth)- stimulated cortisol01240
Withdrew: Withdrawal by subject11000
Withdrew: Lost to follow-up00111
Withdrew: Dose arm exceeds maximum tolerated dose (mtd)00070
Withdrew: Protocol violation00001

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants

As per the protocol, MTD is the dose at which 4 participants exhibited ACTH-stimulated cortisol results \<400 nanomoles per liter (nmol/L). The change in the distribution across the treatments were analyzed using 1- way analysis of variance (ANOVA) for continuous variables.

Time frame:
Up to Week 6
Reported as:
Number · milligrams (mg)
Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants
milligrams (mg)LCI699
Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants1.30 (0.88 to 1.81)
SecondaryLCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants

Exposure-response relationship was assessed using ACTH stimulation test. Tests were done 2 hours after study drug administration (i.e., at peak LCI699 concentrations). An increase in cortisol greater than \>500 nmol at 60 minutes after ACTH administration was expected.

Time frame:
Up to Week 6
Reported as:
Mean · nanomoles per liter (nmol/L)
LCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants
nanomoles per liter (nmol/L)Cohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QDPlacebo
Day 7690.0 ± 32.288669.40 ± 30.903625.06 ± 30.965562.04 ± 30.325799.06 ± 31.161
Day 28634.87 ± 32.181573.41 ± 30.642554.79 ± 29.466539.09 ± 32.826804.86 ± 29.786
Day 42647.51 ± 45.593626.08 ± 45.441539.68 ± 37.146479.91 ± 48.865812.91 ± 39.096
SecondaryLCI699 Plasma Concentration Post LCI699 Administration at Day 7
Time frame:
Predose and 3 hours post-dose on Day 7
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
LCI699 Plasma Concentration Post LCI699 Administration at Day 7
nanogram per milliliter (ng/mL)Cohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QD
LCI699 Plasma Concentration Post LCI699 Administration at Day 71.51 ± 362.88 ± 413.92 ± 316.73 ± 23
SecondaryMaximum Plasma Concentration (Cmax) of LCI699
Time frame:
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of LCI699
ng/mLCohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QD
Maximum Plasma Concentration (Cmax) of LCI6991.42 ± 362.94 ± 354.62 ± 358.86 ± 21
SecondaryTime of Maximum Plasma Concentration (Tmax) of LCI699
Time frame:
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Reported as:
Median · hour (hr)
Time of Maximum Plasma Concentration (Tmax) of LCI699
hour (hr)Cohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QD
Time of Maximum Plasma Concentration (Tmax) of LCI6992.21 (1.0 to 4.0)1.00 (1.0 to 4.0)1.00 (0.5 to 4.0)1.00 (1.0 to 3.0)
SecondaryArea Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)
Time frame:
Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)
nanogram*hour per milliliter (ng*hr/mL)Cohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QD
Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)6.60 ± 4214.1 ± 3024.1 ± 3946.4 ± 13
SecondaryArea Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699
Time frame:
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699
ng*hr/mLCohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QD
Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI6999.23 ± 5018.8 ± 5130.6 ± 4168.9 ± 19
SecondaryApparent Terminal Half-life (T1/2) of LCI699
Time frame:
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Reported as:
Geometric mean · hr
Apparent Terminal Half-life (T1/2) of LCI699
hrCohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QD
Apparent Terminal Half-life (T1/2) of LCI6994.67 ± 373.79 ± 435.52 ± 334.90 ± 17
SecondaryNumber of Participants With Adverse Event (AEs)

An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives.

Time frame:
Up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event (AEs)
ParticipantsCohort A: LCI699 0.5 mg QDCohort A: LCI699 1 mg QDCohort B1: LCI699 1 mg BIDCohort B1: LCI699 2 mg QDPlacebo
Number of Participants With Adverse Event (AEs)69101010
SecondaryPercentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing blood pressure (BP) and heart rate (HR) measurements were performed. MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)
percentage of participantsCohort A: LCI699 0.5 mg QDCohort A: LCI699 1 mg QDCohort B1: LCI699 1 mg BIDCohort B1: LCI699 2 mg QDPlacebo
MSSBP Response58.350.069.276.961.5
MSSBP Control50.041.761.576.953.8
SecondaryPercentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP

Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing BP and HR measurements were performed. MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>= 10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP
percentage of participantsCohort A: LCI699 0.5 mg QDCohort A: LCI699 1 mg QDCohort B1: LCI699 1 mg BIDCohort B1: LCI699 2 mg QDPlacebo
MSDBP Response58.366.710076.961.5
MSDBP Control58.366.776.976.946.2

Adverse events

Collected over Up to 8 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: LCI699 0.5 mg QD0/12 (0%)0/12 (0%)6/12 (50%)
Cohort A: LCI699 1.0 mg QD0/12 (0%)0/12 (0%)9/12 (75%)
Cohort B1: LCI699 1.0 mg BID0/13 (0%)0/13 (0%)10/13 (76.9%)
Cohort B1: LCI699 2.0 mg QD0/13 (0%)0/13 (0%)10/13 (76.9%)
Placebo0/13 (0%)0/13 (0%)10/13 (76.9%)
Most frequent other events
Showing 10 of 57
Most frequent other events
EventCohort A: LCI699 0.5 mg QDCohort A: LCI699 1.0 mg QDCohort B1: LCI699 1.0 mg BIDCohort B1: LCI699 2.0 mg QDPlacebo
HeadacheNervous system disorders1/124/122/132/133/13
ACTH stimulation test abnormalInvestigations0/121/122/134/130/13
DiarrhoeaGastrointestinal disorders0/121/122/130/133/13
DizzinessNervous system disorders2/120/123/130/131/13
VomitingGastrointestinal disorders0/122/120/130/131/13
SinusitisInfections and infestations0/120/121/132/130/13
AnaemiaBlood and lymphatic system disorders1/120/120/130/130/13
PalpitationsCardiac disorders0/121/120/130/130/13
Abdominal painGastrointestinal disorders0/121/120/130/130/13
Dry mouthGastrointestinal disorders1/120/120/130/130/13

Baseline characteristics

Full analysis set (FAS) population included all participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort A: LCI699 0.5 mg QDCohort A: LCI699 1 mg QDCohort B1: LCI699 1 mg BIDCohort B1: LCI699 2 mg QDPlaceboTotal
Mean56.1 ± 6.3754.2 ± 16.0157.9 ± 9.0956.2 ± 10.3756.8 ± 10.0856.3 ± 10.52
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: LCI699 0.5 mg QDCohort A: LCI699 1 mg QDCohort B1: LCI699 1 mg BIDCohort B1: LCI699 2 mg QDPlaceboTotal
Female4535421
Male87108942
08

Study locations

11 sites
  • Impact Clinical Trials
    Beverly Hills, California 90211, United States
  • Associated Pharmaceutical Research Center, Inc
    Buena Park, California 90620, United States
  • Innovative Clinical Research, Inc
    Harbor City, California 90710, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90806, United States
  • Metro Clinical Research
    Littleton, Colorado 80120, United States
  • Clinical Study Center of Asheville, LLC
    Asheville, North Carolina 28801, United States
  • Northstate Clinical Research
    Lenoir, North Carolina 28645, United States
  • Tipton Medical & Diagnostic Center
    Tipton, Pennsylvania 16684, United States
  • Punzi Medical Center
    Carrollton, Texas 75006, United States
  • dgd Research, Inc
    San Antonio, Texas 78229, United States
  • Encode Clinic
    Reykjavik, SA, Iceland
09

References and documents

Publications

  • Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013 Oct;31(10):2085-93. doi: 10.1097/HJH.0b013e328363570c. PubMed 24107737 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2009 to primary completion in Aug 2009, 6 months.

Results were first posted in Jun 2021, 11 years 9 months after primary completion. A results delay was requested in Nov 2012.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 6 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2009
First posted
Jan 6, 2009
StartActual
Jan 14, 2009
Primary completionActual
Aug 12, 2009
CompletionActual
Aug 12, 2009
Results delay requested
Nov 30, 2012
Results first posted
Jun 2, 2021
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00817414
Lead sponsor
Novartis
Collaborators
Great Lakes Drug Development, Inc., Integrium
Responsible party
Sponsor
First posted
Jan 6, 2009
Start date
Jan 14, 2009
Primary completion
Aug 12, 2009
Completion
Aug 12, 2009
Results posted
Jun 2, 2021
Last update
Jun 2, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion